Checkmate 914

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

Checkmate 914

Sep 27, 2024, 13:30 | Insight

Yüksel Ürün: Adjuvant nivolumab vs placebo in localized RCC patients at high recurrence risk post-nephrectomy by Robert J. Motzer

Yüksel Ürün shared a post on X: "CheckMate 914 (Part B) failed to show DFS improvement…

Jan 29, 2024, 17:46 | Insight

Roberto Iacovelli: Different results from 2 phase 3 studies on adjuvant IO for mRCC... what's the reason?

Roberto Iacovelli, Associate Professor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome…

Jan 27, 2024, 17:17 | Societies

ASCO GU 2024 – New insights in clear cell renal cancer (RCC) – Adjuvant perspectives

By Marcos Franca During the morning in ASCO GU 2024 meeting, in San Francisco –…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023